Plasmapheresis adjusts inflammatory responses in potential kidney transplant recipients

Transplantation

Volumn 95, Issue 8, 2013, Pages 1021-1029

  Sadeghi, Mahmoud ^a   Daniel, Volker ^a   Wang, Haihao ^a   Zeier, Martin ^a   Schemmer, Peter ^a   Mehrabi, Arianeb ^a   Lahdou, Imad ^a   Morath, Christian ^a   Opelz, Gerhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cytokines; Kidney; Neopterin; Plasmapheresis; Transplantation

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; GAMMA INTERFERON; GANCICLOVIR; HLA DR ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOPTERIN; PANEL REACTIVE ANTIBODY; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD FILTER; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HEMODIALYSIS; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NATURAL KILLER CELL; PLASMAPHERESIS; PRIORITY JOURNAL; SEX DIFFERENCE; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIBODIES; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOMODULATION; INFLAMMATION MEDIATORS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPTERIN; PLASMAPHERESIS;

EID: 84876522721     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318286191b     Document Type: Article

References (58)

1. Pruijm MT, Cherpillod A, Vogt B, et al. Plasmapheresis: technique, complications and indications. Rev Med Suisse 2008; 4: 581.
2. Tan HK, Hart G. Plasma filtration. Ann Acad Med Singapore 2005; 34: 615.
3. El-Ghariani K, Unsworth DJ. Therapeutic apheresisVplasmapheresis. Clin Med 2006; 6: 343.
4. Beimler JH, Susal C, Zeier M. Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin Transplant 2006; 20(Suppl 17): 7.
5. Morath C, Beimler J, Opelz G, et al. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 2011; 90: 645.
6. Susal C, Morath C. Current approaches to the management of highly sensitized kidney transplant patients. Tissue Antigens 2011; 77: 177.
7. Toft P, Schmidt R, Broechner AC, et al. Effect of plasmapheresis on the immune system in endotoxin-induced sepsis. Blood Purif 2008; 26: 145.
8. Hoffmann JN, Hartl WH, Deppisch R, et al. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int 1995; 48: 1563.
9. Hoffmann JN, Hartl WH, Deppisch R, et al. Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis. Intensive Care Med 1996; 22: 1360.
10. Bengsch S, Boos KS, Nagel D, et al. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 2005; 23: 494.
11. Reeves JH. A review of plasma exchange in sepsis. Blood Purif 2002; 20: 282.
12. Bender T, Polner K, Barna I, et al. Effect of plasmapheresis on serum beta-endorphin levels. Blood Purif 2005; 23: 141.
13. Kyles DM, Baltimore J. Adjunctive use of plasmapheresis and intravenous immunoglobulin therapy in sepsis: a case report. Am J Crit Care 2005; 14: 109.
14. Chien PJ, Yeh JH, Chiu HC, et al. Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis. Eur J Neurol 2011; 18: 1350.
15. Dau PC, Callahan JP. Immune modulation during treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs. Clin Immunol Immunopathol 1994; 70: 159.
16. Yeh JH, Chien PJ, Hsueh YM, et al. Changes in the lymphocyte subset after double-filtration plasmapheresis. Am J Clin Pathol 2007; 128: 940.
17. Barath S, Soltesz P, Kiss E, et al. The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4+CD25(high)FoxP3+ regulatory T cells during repeated plas-mapheresis treatments of patients. Autoimmunity 2007; 40: 521.
18. Mao Q, Terasaki PI, Cai J, et al. Analysis of HLA class I specific antibodies in patients with failed allografts. Transplantation 2007; 83: 54.
19. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
20. Narita YM, Hirahara K, Mizukawa Y, et al. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol 2011; 38: 236.
21. Malyak M, Guthridge JM, Hance KR, et al. Characterization of a low molecular weight isoform of IL-1 receptor antagonist. J Immunol 1998; 161: 1997.
22. Linevsky JK, Pothoulakis C, Keates S, et al. IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol 1997; 273(6 Pt 1): G1333.
23. Bogner JR, Junge-Hulsing B, Kronawitter U, et al. Expansion of neopterin and beta 2-microglobulin in cerebrospinal fluid reaches maximum levels early and late in the course of human immunodeficiency virus infection. Clin Investig 1992; 70: 665.
24. Lockwood CM, Worlledge S, Nicholas A, et al. Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 1979; 300: 524.
25. Aeschbacher B, Haeberli A, Nydegger UE. Donor safety and plasma quality in automated plasmapheresis. Comparison of two filter materials. Vox Sang 1989; 57: 104.
26. Suzuki M, Yamane S, Matsugane T, et al. Evaluation of double filtration plasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hy-percholesterolemia patients. Artif Organs 1996; 20: 296.
27. de Jager W, Hoppenreijs EP, Wulffraat NM, et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007; 66: 589.
28. Poole S, Bird TA, Selkirk S, et al. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 1990; 2: 416.
29. Turnbull AV, Prehar S, Kennedy AR, et al. Interleukin-6 is an afferent signal to the hypothalamo-pituitary-adrenal axis during local inflammation in mice. Endocrinology 2003; 144: 1894.
30. Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci 1998; 856: 1.
31. Pereira BJ, Poutsiaka DD, King AJ, et al. In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. Kidney Int 1992; 42: 1419.
32. Tran MT, Lausch RN, Oakes JE. Substance P differentially stimulates IL-8 synthesis in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2000; 41: 3871.
33. Muzio M, Re F, Sironi M, et al. Interleukin-13 induces the production of interleukin-1 receptor antagonist (IL-1ra) and the expression of the mRNA for the intracellular (keratinocyte) form of IL-1ra in human myelomonocytic cells. Blood 1994; 83: 1738.
34. Tesar V, Jelinkova E, Masek Z, et al. Influence of plasma exchange on serum levels of cytokines and adhesion molecules in ANCA-positive renal vasculitis. Blood Purif 1998; 16: 72.
35. Grazia ZM, Claudia S. Effects of selective H.E.L.P. LDL-apheresis on plasma inflammatory markers concentration in severe dyslipidemia: implication for anti-inflammatory response. Cytokine 2011; 56: 850.
36. Yeh JH, Wang SH, Chien PJ, et al. Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis. Eur J Neurol 2009; 16: 1318.
37. Soltesz P, Aleksza M, Antal-Szalmas P, et al. Plasmapheresis modulates Th1/Th2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmic cytokines. Autoimmunity 2002; 35: 51.
38. Levy H, Ash SR, Knab W, et al. Systemic inflammatory response syndrome treatment by powdered sorbent pheresis: the BioLogic-Detoxification Plasma Filtration System. ASAIO J 1998; 44: M659.
39. Hehmke B, Salzsieder E, Matic GB, et al. Immunoadsorption of im-munoglobulins alters intracytoplasmic type 1 and type 2 T cell cytokine production in patients with refractory autoimmune diseases. Ther Apher2005; 4: 296.
40. Hovland A, Hardersen R, Mollnes TE, et al. Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia. JOP 2010; 11: 467.
41. Skerrett D, Mor E, Curtiss S, et al. Plasmapheresis in primary dysfunction of hepatic transplants. J Clin Apher 1996; 11: 10.
42. Gabay C, Gigley J, Sipe J, et al. Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo. Eur J Immunol 2001; 31: 490.
43. Gabay C, Porter B, Fantuzzi G, et al. Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of in-tracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo. J Immunol 1997; 159: 5905.
44. Hatano Y, Katagiri K, Arakawa S, et al. Successful treatment by doublefiltration plasmapheresis of a patient with bullous pemphigoid: effects in vivo on transcripts of several genes for chemokines and cytokines in peripheral blood mononuclear cells. Br J Dermatol 2003; 148: 573.
45. Paglieroni T, Caggiano V, MacKenzie MR. Effects of plasmapheresis on peripheral blood mononuclear cell populations from patients with macroglobulinemia. J Clin Apher 1987; 3: 202.
46. Kiprov DD, Dau PC, Morand P. The effect of plasmapheresis and drug immunosuppression on T-cell subsets as defined by monoclonal antibodies. J Clin Apher 1983; 1: 57.
47. Hueso M, Mestre M, Benavente Y, et al. Pretransplant low CD3+ CD25high cell counts or a low CD3+CD25high/CD3+HLA-DR+ ratio are associated with an increased risk to acute renal allograft rejection. Transplantation 2011; 92: 536.
48. Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther 2001; 26: 319.
49. Fuchs D, Hausen A, Reibnegger G, et al. Neopterin levels in long-term hemodialysis. Clin Nephrol 1988; 30: 220.
50. Putz D, Barnas U, Luger A, et al. Biocompatibility of high-flux membranes. Int J Artif Organs 1992; 15: 456.
51. Schafer AJ, Daniel V, Dreikorn K, et al. Assessment of plasma neopterin in clinical kidney transplantation. Transplantation 1986; 41: 454.
52. Sadeghi M, Daniel V, Weimer R, et al. Pre-transplant Th1 and post-transplant Th2 cytokine patterns are associated with early acute rejection in renal transplant recipients. Clin Transplant 2003; 17: 151.
53. Lauzurica R, Pastor MC, Bayes B, et al. Pretransplant inflammation: a risk factor for delayed graft function? J Nephrol 2008; 21: 221.
54. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
55. Shankarkumar U, Ghosh K, Mohanty D. The human leucocyte antigen (HLA) system. J Assoc Physicians India 2002; 50: 916.
56. Costa E, Lima M, Alves JM, et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under he-modialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol 2008; 28: 268.
57. Ozdemir BH, Aksoy PK, Haberal AN, et al. Relationship of HLA-DR expression to rejection and mononuclear cell infiltration in renal allo-graft biopsies. Ren Fail 2004; 26: 247.
58. Paglieroni TG, Holland PV. Effects of serial plasmapheresis on serum IgA levels in IgA-deficient blood donors with IgA-suppressor T cells. Transfusion 1992; 32: 139.